Cisplatin

A chemotherapy agent that interferes with DNA replication and kills cancer cells; induces growth arrest and/or apoptosis in most cancer cell types; an alkylating agent for treatment of a number of cancers.Chemotherapeutic Agents Approved (In Vitro) :Cisplatin (CDDP) causes apoptosis of HeLa cells in a dose-dependent manner, with a concentration of 30 μM Cisplatin resulting in death of greater than 90% of the cell population by 24 h of treatment. The kinetics of Cisplatin-induced apoptosis are examined using a 30 μM concentration. Cisplatin Activates the MEK/ERK Signaling Pathway, 20 and 30 μM Cisplatin, both of which results in significant apoptosis, leads to strong activation of ERK.Cisplatin (50 μM) produces time-dependent apoptosis in renal proximal tubular cell (RPTCs), causing cell shrinkage, a 50-fold increase in caspase 3 activity, a 4-fold increase in phosphatidylserine externalization, and 5- and 15-fold increases in chromatin condensation and DNA hypoploidy, respectively. (In Vivo) :In melanoma-bearing mice, Cisplatin (CDDP; 4 mg/kg B.W.) reduces the size and weight of the solid tumors, and HemoHIM supplementation with Cisplatin enhances the decrease of both the tumor size and weight.Cisplatin administration results in significant increases in the kidney weight as a percentage of the total body weight, urine volume, serum creatinine, and blood urea nitrogen by about 132, 315, 797, and 556% in comparison with the control rats, respectively.

15663-27-1

CDDP | cis-Diaminodichloroplatinum

>98% (HPLC)

DMSO: ≥ 31 mg/mL (DMSO can inactivate Cisplatin's activity)

Cl[Pt-2] ([NH3+]) ([NH3+]) Cl

Cl2H6N2Pt

300.051

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.